Fungicidal Power You Can Trust®

High-performance antifungal1,2

NAFTIN® (Naftifine HCl) Gel, 2% delivers the proven efficacy of an allylamine with the safety profile of vehicle1

  • A fungicidal allylamine that attacks offending microorganisms—highest efficacy observed at 6 weeks (4 weeks post last treatment)1
  • Adverse events comparable to vehicle1:
    • Application site reactions were the most common adverse reactions seen in clinical trials with NAFTIN® Gel, 2% (2%) vs vehicle (1%)

Harnessing the power of a fungicidal allylamine in a 2% gel1

Clinically proven to clear interdigital tinea pedis even after treatment ends1

Primary endpoint
Complete cure at week 6 (4 weeks post last treatment) with NAFTIN® Gel, 2%1

View more data

Study 1

  • Complete cure rates of 17% were achieved at 4 weeks post last treatment with NAFTIN® Gel vs 2% with vehicle1,a
  • Treatment effectiveness rates of 54% were achieved at week 6
     (4 weeks post last treatment) with NAFTIN® Gel vs 6% with vehicle1,b
  • Mycological cure rates of 65% were achieved at week 6 (4 weeks post last treatment) with NAFTIN® Gel, 2% vs 14% with vehicle1,c

Study 1

Effective against interdigital tinea pedis at week 6 (4 weeks post last treatment)1

COMPLETE CURE

TREATMENT EFFECTIVENESS

MYCOLOGICAL CURE

aComplete cure is a composite endpoint of both mycological cure and clinical cure.
 Clinical cure is defined as the absence of erythema, pruritus, and scaling (grade of 0).1

bTreatment effectiveness is a negative KOH preparation and negative dermatophyte culture,
 erythema, scaling, and pruritus grades of 0 or 1 (absent or nearly absent).1

cMycological cure is defined as negative KOH and dermatophyte culture.1

Study design: 2 randomized, double-blind, vehicle-controlled, multicenter, 6-week studies in 1175 subjects with interdigital tinea pedis; in study 1, NAFTIN® Gel, 2% (n=382) was compared with vehicle (n=179) at week 6 after a 2-week treatment for interdigital tinea pedis; and in study 2, NAFTIN® Gel, 2% (n=400) was compared with vehicle (n=213) at week 6 after a 2-week treatment for interdigital tinea pedis.1

View more data

Study 2

  • Complete cure rates of 26% were achieved at week 6 (4 weeks post last treatment) with NAFTIN® Gel 2% vs 3% with vehicle1,a
  • Treatment effectiveness rates of 51% were achieved at week 6
     (4 weeks post last treatment) with NAFTIN® Gel, 2% vs 7% with vehicle1,b
  • Mycological cure rates of 59% were achieved at week 6 (4 weeks post last treatment) with NAFTIN® Gel, 2% vs 10% with vehicle1,c

Study 2

Effective against interdigital tinea pedis at week 6 (4 weeks post last treatment)1

COMPLETE CURE

TREATMENT EFFECTIVENESS

MYCOLOGICAL CURE

aComplete cure is a composite endpoint of both mycological cure and clinical cure.
 Clinical cure is defined as the absence of erythema, pruritus, and scaling (grade of 0).1

bTreatment effectiveness is a negative KOH preparation and negative dermatophyte culture,
 erythema, scaling, and pruritus grades of 0 or 1 (absent or nearly absent).1

cMycological cure is defined as negative KOH and dermatophyte culture.1

Study design: 2 randomized, double-blind, vehicle-controlled, multicenter, 6-week studies in 1175 subjects with interdigital tinea pedis; in study 1, NAFTIN® Gel, 2% (n=382) was compared with vehicle (n=179) at week 6 after a 2-week treatment for interdigital tinea pedis; and in study 2, NAFTIN® Gel, 2% (n=400) was compared with vehicle (n=213) at week 6 after a 2-week treatment for interdigital tinea pedis.1

ExpandCollapseClick to See Complete Safety InformationClose

NAFTIN® (Naftifine HCl) Gel, 2%

INDICATIONS AND USAGE

NAFTIN GEL, 2% is an allylamine antifungal indicated for the treatment of interdigital tinea pedis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum in patients 12 years of age and older.

IMPORTANT SAFETY INFORMATION ADVERSE REACTIONS

In clinical trials with NAFTIN Gel, 2%, the most common adverse reactions (2%) were application site reactions.

WARNINGS AND PRECAUTIONS

If redness or irritation develops with the use of NAFTIN Gel, 2%, treatment should be discontinued.

Please click here for NAFTIN full prescribing information

References: 1. NAFTIN® Gel (Naftifine HCI), 2% Prescribing Information. Greensboro, NC: Merz Pharmaceuticals, LLC; October 2014. 2. Brennan B, Leyden JJ. Overview of topical therapy for common superficial fungal infections and the role of new topical agents. J Am Acad Dermatol. 1997;36:S3-S8. 3. NAFTIN 2% Co-Pay Savings Offer. Sebela Pharmaceuticals Inc., January 2017. 4. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration/Center for Drug Evaluation and Research website. http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No=019599&TABLE1=OB_Rx. Accessed February 22, 2016. 2015. 5. Parish LC, Parish JL, Routh HB, et al. A randomized, double-blind, vehicle-controlled efficacy and safety study of naftifine 2% cream in the treatment of tinea pedis. J Drugs Dermatol. November 2011;10(11):1282-1288. 6. Parish LC, Parish JL, Routh HB, et al. A double-blind, randomized, vehicle-controlled study evaluating the efficacy and safety of naftifine 2% cream in tinea cruris. J Drugs Dermatol. October 2011;10(10):1142-1147. 7. Vlahovic TC. Choosing the right vehicle. Podiatry management. June/July 2008;209-218. 8. Robbins CM, Elston DM. Tinea pedis treatment & management. Medscape Web site. http://emedicine.medscape.com/article/1091684-overview. Updated November 19, 2015. Accessed February 22, 2016. 9. Phillips, RM, Rosen T. Topical antifungal agents. Allylamines and benzylamines. In: Wolverton, SE, ed. Comprehensive Dermatologic Drug Therapy. 3rd ed. Elsevier Inc. Ebook; 2013:460-472.